Expert opinion on immunotherapy induced diabetes.
Fiche publication
Date publication
juillet 2018
Journal
Annales d'endocrinologie
Auteurs
Membres identifiés du Cancéropôle Est :
Pr VERGES Bruno
Tous les auteurs :
Smati S, Buffier P, Bouillet B, Archambeaud F, Vergès B, Cariou B
Lien Pubmed
Résumé
Immunotherapy often incurs side-effects, mainly involving the skin, digestive tract and endocrine system. The most frequent endocrine side-effects involve the pituitary and thyroid glands. Cases of insulin-dependent diabetes, whether autoimmune or not (type 1 or 1B) have been reported with PD-1/PD-L1 inhibitors, alone or in association with anti-CTLA-4 antibodies, and were systematically associated with sudden-onset insulinopenia, frequently leading to ketoacidosis or fulminant diabetes, requiring first-line insulin therapy. This adverse effect has not so far been reported with anti-CTLA-4 monotherapy.
Mots clés
Antibodies, Monoclonal, adverse effects, Consensus, Diabetes Mellitus, chemically induced, Diabetes Mellitus, Type 1, chemically induced, Diabetes Mellitus, Type 2, chemically induced, Humans, Immunotherapy, adverse effects, Prognosis
Référence
Ann. Endocrinol. (Paris). 2018 Jul 25;: